15.04.2015 • NewsDevelopmentfootprintmarketing

Recipharm Buys Synthonics Preferred Stock

Swedish drugmaker Recipharm has acquired $2 million worth of preferred stock in Synthonics and has promised to buy an additional $2 million of the stock, contingent on the US metal coordination chemistry specialist achieving certain milestones expected during 2016.

In connection with the investment, Recipharm's Carl-Johan Spak has joined Synthonics' board of directors.

Additionally, the two companies have signed a joint development agreement, giving Synthonics access to Recipharm's expertise in drug development, marketing and manufacturing in exchange for a royalty payment on certain compounds.

The pharmaceutical firms first began collaborating in 2013 with the signing of a joint marketing built around Synthomer's drug delivery technology for metal coordination of pharmaceutical APIs.

Synthonics CEO Ken Slepicka said his company is "delighted" to join Recipharm in helping advance promising molecules to market. He added that the agreement and financial support "will help us further advance several of our current projects to commercialization."

Carl-Johan Spak, executive vice president, technology and development at Recipharm, said the transaction expands the Swedish company's footprint in the US and builds on the existing joint marketing agreement with Synthonics.

 

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.